Adempas helps lower risk in PAH patients, newer risk model confirms
People with pulmonary arterial hypertension (PAH) seen to be at an intermediate risk of death ā whether in the low or high range of that middle-level risk ā were more likely to have better outcomes when treated with Adempas (riociguat) than given a placebo in a Phase 3…